Procter & Gamble’s feminine care product sales grew 6% organically over the past three years and the firm anticipates stronger growth ahead in a global market for menstrual and incontinence care already at $34bn.
P&G's Feminine Care Sales Up As Incontinence, Menstrual Products Get Superiority Attention
Procter & Gamble CEO Jon Moeller and and feminine products chief Jennifer Davis outline firm's strategies and focus areas in sustainability and superiority in 2022. While more than half consumers are interested in natural or more sustainable products, few will settle for lesser product performance, Davis said. But they appear willing to pay a premium for products made with sustainable materials.

More from Strategy
Chinese consumers are now routinely taking supplements for a variety of health reasons, helping to drive up sales of the Swisse Plus+ brand by 20% in 2024.
Growing use of GLP-1 receptor agonists is having a positive knock-on effect on the dietary supplements market, reports OptiBiotix Health, marketer of the SlimBiome weight management prebiotic.
By taking a majority stake in dynamic dietary supplements firm Braineffect, Germany's Schwabe can reach a new, younger target audience for its OTC herbal medicines.
A round-up of the latest consumer health industry appointments: GSCF elects chair; Kenvue hires Northern Europe head; Barentz names chief commercial officer.
More from Business
Bayer Consumer Health hopes its new InflammAge saliva-based biomarker can help “revolutionize self-care and how people can manage their aging journey.”
A week after announcing 2024 full-year and fourth-quarter results, the firm says its corporate name will be Niagen Bioscience Inc. starting 19 March. It stated in its latest results that during 2024 it launched Niagen Plus line of pharmaceutical-grade Niagen.
Direct seller has deals to fully acquire and 51% ownership of Link BioSciences, which formulates personalized supplements. It also announced a deal to acquire Pruvit Ventures, ketone supplements direct seller.